New combo may boost stem cell harvest for myeloma patients

NCT ID NCT06514508

Recruiting now Disease control Sponsor: Guangzhou Gloria Biosciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding motixafortide to standard G-CSF helps collect more stem cells for a bone marrow transplant in people with multiple myeloma. About 60 Chinese adults with active myeloma will receive either the drug combo or a placebo before stem cell collection. The goal is to see if the combo leads to enough cells in fewer sessions, making the transplant process smoother.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Harbin The First Hospital
NOT_YET_RECRUITING

Harbin, Hei Longjiang, 150010, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100044, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.